Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and
AUTHOR(S)Steven Peterson, Ph.D. The project evaluated anticonvulsant and neuroprotectant properties of novel medical countermeasures to lithium-pilocarpine-induced status epilepticus (SE)used here as a model of organophosphorus nerve agents. Although mefenamate induced modest anticonvulsant effects, survival was reduced and the SE-induced neuropathology was exacerbated. Nicotinamide induced only modest anticonvulsant and neuroprotectant activity at the doses tested. N-acetylcysteine was not anticonvulsant but enhanced both neurological deficit and neuropathology. PBN, but not S-PBN, induced significant neuroprotection.
PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES)8ACPC induced neuroprotection in temporal regions without anticonvulsant activity. D-cycloserine had no effect.Propofol induced significant neuroprotection and anticonvulsant activity in the rat model tested. It is recommended that PBN and ACPC be tested in multiple dose regimens for long term neuroprotetion in nerve agent SE.
INTRODUCTIONThis project tested novel treatment strategies for the N-methyl-D-aspartic acid (NMDA) component of organophosphorous (OP) nerve agents that are intended to complement or improve current treatments. OP agents induce an initial cholinergic receptor over stimulation that is followed by a glutamatergic over stimulation of NMDA receptors. The excessive NMDA activation and excitotoxicity results in the status epilepticus (SE), neurological deficit and neuropathology associated with OP intoxication. The lithium-pilocarpine (Li-pilo) model of cholinergic convulsions in rats is used as the experimental model of OP nerve agent-induced SE. The project tests neuroprotectants that protect the brain from seizure-induced neuropathology by interfering with NMDA receptor-mediated intracellular excitotoxicity mechanisms. Experimental parameters used in these studies to assess the test drug activity were: 1) electrocorticograph (ECoG) determination of continuous high amplitude spiking as a measure of SE duration; 2) spontaneous activity before and after SE as a measure of neurological deficit; 3) neuropathology in brain regions damaged by Li-pilo SE.The candidate medical countermeasures tested in the last 12 months of the project were mefenamate, nicotinamide and N-acetylcysteine. The results of those studies are presented in detail. The results of the oc-phenyl-N-tert-butylnitrone (PBN) study are provided in the Appendix in manuscript form (App...